Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
23 mai 2023 12h57 HE
|
Curium
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
14 mars 2023 10h46 HE
|
Curium
To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion and 10-Year Commitment to St. Louis, MO
02 mars 2023 07h44 HE
|
Curium
Renaissance in nuclear medicine to attract top St. Louis talentNorth America Headquarters to call Westport Plaza home for the next 10 yearsOver 100 new jobs in the next 3 years ST. LOUIS, March 02,...
Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99
21 déc. 2022 10h26 HE
|
Curium
PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20...
Curium’s Customers to Benefit From Mo-99 Production Restart
23 nov. 2022 11h50 HE
|
Curium
PARIS, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the restarting of a production cycle at the HFR reactor in Petten,...
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
22 nov. 2022 00h01 HE
|
Curium
ST. LOUIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that it intends to submit updated labeling to the U.S. Food and Drug Administration...
Nuclear Medicine Outlook: Proven Molybdenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
08 nov. 2022 13h05 HE
|
Curium
Measures in place minimize impact of near-term molybdenum-99 shortageMore than ten years of Mo-99 supply chain resilienceCooperation, investment, and facility upgrades for the benefit of patients ...
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
27 juin 2022 01h00 HE
|
Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
12 mai 2022 01h05 HE
|
Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
03 mai 2022 01h05 HE
|
Curium
ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized...